Though existing research has shown that gastric bypass surgery resolves type 2 diabetes, the reason has remained unclear. A research team led by Nicholas Stylopoulos, HMS assistant professor of pediatrics at Boston Children’s Hospital, has identified the small intestine—widely believed to be a passive organ—as the major contributor to the body’s metabolism, based on a study in rats. The report appears in the July 26, 2013, issue of Science.
Weight loss and improved diabetes often go hand in hand, but type 2 diabetes often disappears even before weight loss occurs after gastric bypass. To investigate why this happens, Stylopoulos and his team spent one year studying rats. They observed that after gastric bypass surgery, the small intestine changes the way it processes glucose. The team saw the intestine using and disposing of glucose, thereby regulating blood glucose levels in the rest of the body and helping to eliminate type 2 diabetes.
“We have seen type 2 diabetes resolve in humans after gastric bypass, but have never known why,” said Stylopoulos. “People have been focusing on hormones, fat and muscle, but we have shown in this study that the answer lies somewhere in the small intestine most of the time.”
Gastric bypass surgery, a weight-loss treatment typically reserved for severely obese patients, reroutes food into a small pouch of the stomach and bypasses the rest of the stomach and duodenum. Before gastric bypass, intestines typically do not contain GLUT-1, a specific transporter responsible for removing glucose from circulation and utilizing it within the organ. After gastric bypass, the researchers found that the intestine reprograms itself to contain GLUT-1, taking glucose from circulation and disposing of it, swiftly stabilizing blood glucose levels in the rest of the body.
“Previously, we had not considered the intestine as a major glucose-utilizing organ. We have found this process is exactly what happens after surgery,” said Stylopoulos.
Based on their findings, Stylopoulos and his colleagues found that type 2 diabetes was resolved in 100 percent of the rats that underwent gastric bypass. Sixty-four percent of type 2 diabetes was resolved by the intestine, and the researchers hypothesize that the remaining 36 percent may be due to weight loss or other factors.
These findings pave the way for future investigations of how to create a medical pathway to mimic the intestine’s reprogramming, without the surgery. “With further research, we may find ways to bypass the bypass,” said Stylopoulos. “The results of our study are promising because, unlike the brain and other organs, intestines are easily accessible. Furthermore, since cells in the intestine have such a short lifespan, we can easily study and pharmacologically manipulate them to use glucose, without long-term problems.”
This research was supported with funds from the National Institutes of Health and the Division of Endocrinology, Department of Medicine and the Clinical and Translational Executive Committee at Boston Children’s Hospital.
ABC 15
http://www.abc15.com/dpp/news/local_news/investigations/new-diet-drug-that-targets-appetite-suppression-in-the-brain
A new FDA approved diet pill called Belviq just went on the market. Belviq make people more likely to succeed with weight loss since they feel full more quickly and it reduces food cravings. People who take Belviq with diet and exercise were 2 times more likely to lose 5% body weight and 3 times more likely to lose 10% body weight than the people who just did diet and exercise alone. The label states that if you do not lose 5% of your body weight in 12 weeks then consider stopping. Those that do respond in 12 (about 45% of patients) weeks go on to lose over 10% of their body weight in one year. Losing 22 pounds for a 220 pound person is life changing. So 45% of those taking Belviq lose significant amount of weight.
Belviq has a second mode of action to reduce blood sugar which may end up preventing diabetes in many cases. Diabetics and pre-diabetics who took Belviq, REGARDLESS of weight loss, saw their blood sugar numbers drop by double digit percentages. IE HbA1c -0.9 to -1.2 and fasting glucose feel -27. The cost of medications to reduce HbA1c levels exceeds the cost of Belviq. (seeArena’s BloomDM phase III trial) These reductions in diabetic symptoms plus the weight loss at the same time makes Belviq a medical bargain.